Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
Search results
530 results
-
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]
In development [GID-TA10806] Expected publication date: TBC
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: TBC
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 23 March 2022
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]
In development [GID-TA10644] Expected publication date: 17 March 2021
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]
In development [GID-TA10532] Expected publication date: 21 April 2021
-
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]
In development [GID-TA10619] Expected publication date: TBC
-
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 05 January 2022
-
Assessment, referral and management of Adrenal dysfunction
In development [GID-NG10052] Expected publication date: TBC
-
Diagnostic services
In development [GID-CGWAVE0773] Expected publication date: TBC
-
Reducing the mortality and morbidity for healthcare associated infections
In development [GID-NG10059] Expected publication date: TBC
-
Hernia
In development [GID-CGWAVE0771] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
In development [GID-TA10402] Expected publication date: TBC
-
Nintedanib for untreated malignant pleural mesothelioma (ID1424)
In development [GID-TA10359] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Head and neck cancer - contusugene ladenovec [ID76]
In development [GID-TAG407] Expected publication date: TBC
-
Lung cancer (non-small cell) - afatinib [ID357]
In development [GID-TAG422] Expected publication date: TBC
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
In development [GID-TAG330] Expected publication date: TBC
-
Prostate cancer (hormone refractory) - atrasentan [ID390]
In development [GID-TAG379] Expected publication date: TBC
-
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
In development [GID-TAG300] Expected publication date: TBC
-
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
In development [GID-TAG440] Expected publication date: TBC
-
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]
In development [GID-TAG410] Expected publication date: TBC
-
Clostridium difficile associated diarrhoea - tolevamer [ID378]
In development [GID-TAG389] Expected publication date: TBC
-
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]
In development [GID-TAG405] Expected publication date: TBC
-
Heart failure (acute decompensated) - nesiritide [ID384]
In development [GID-TAG376] Expected publication date: TBC
-
Atrial fibrillation - idraparinux sodium [ID375]
In development [GID-TAG383] Expected publication date: TBC
-
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]
In development [GID-TAG384] Expected publication date: TBC
-
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
In development [GID-TAG385] Expected publication date: TBC
-
Diabetic retinopathy - ruboxistaurin [ID382]
In development [GID-TAG386] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
In development [GID-TAG388] Expected publication date: TBC
-
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]
In development [GID-TAG391] Expected publication date: TBC
-
Juvenile idiopathic arthritis - adalimumab [ID385]
In development [GID-TAG400] Expected publication date: TBC
-
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
In development [GID-TAG416] Expected publication date: TBC
-
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]
In development [GID-TAG408] Expected publication date: 01 May 2011